{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:04Z","timestamp":1790705944504,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Denser fibrin networks which are relatively resistant to lysis can predispose to post-thrombotic syndrome (PTS). Histidine-rich glycoprotein (HRG), a blood protein displaying antifibrinolytic properties, is present in fibrin clots. We investigated whether HRG may affect the risk of PTS in relation to alterations to fibrin characteristics. In venous thromboembolism (VTE) patients, we evaluated plasma HRG levels, plasma clot permeability, maximum absorbance, clot lysis time and maximum rate of increase in D-dimer levels released from clots after 3\u00a0months of the index event. We excluded patients with cancer and severe comorbidities. After 2\u00a0years of follow-up, 48 patients who developed PTS had 18.6% higher HRG at baseline. Baseline HRG positively correlated with clot lysis time, maximum absorbance, and thrombin-activatable fibrinolysis inhibitor (TAFI) activity but was inversely correlated with plasma clot permeability and maximum rate of increase in D-dimer levels released from clots. On multivariate regression model adjusted for age, fibrinogen and glucose, independent predictors of PTS were recurrent VTE, baseline HRG level, and TAFI activity. VTE recurred in 45 patients, including 30 patients with PTS, and this event showed no association with elevated HRG. Our findings suggest that increased HRG levels might contribute to the development of PTS, in part through prothrombotic fibrin clot properties.<\/jats:p>","DOI":"10.1038\/s41598-020-71437-5","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:03:28Z","timestamp":1599041008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Increased levels of histidine-rich glycoprotein are associated with the development of post-thrombotic syndrome"],"prefix":"10.1038","volume":"10","author":[{"given":"Jakub","family":"Siudut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Plens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"71437_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11239-009-0309-3","volume":"28","author":"AA Ashrani","year":"2009","unstructured":"Ashrani, A. A. & Heit, J. A. Incidence and cost burden of post-thrombotic syndrome. J. Thromb. Thrombolysis. 28, 465\u2013476 (2009).","journal-title":"J. Thromb. Thrombolysis."},{"key":"71437_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1538-7836.2009.03294.x","volume":"7","author":"SR Kahn","year":"2009","unstructured":"Kahn, S. R. et al. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J. Thromb. Haemost. 7, 879\u2013883 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMra055289","volume":"355","author":"JJ Bergan","year":"2006","unstructured":"Bergan, J. J. et al. Chronic venous disease. N. Engl. J. Med. 355, 488\u2013498 (2006).","journal-title":"N. Engl. J. Med."},{"key":"71437_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7326\/0003-4819-149-10-200811180-00004","volume":"149","author":"SR Kahn","year":"2008","unstructured":"Kahn, S. R. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann. Intern. Med. 149, 698\u2013707 (2008).","journal-title":"Ann. Intern. Med."},{"key":"71437_CR5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","volume":"130","author":"SR Kahn","year":"2014","unstructured":"Kahn, S. R. et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 130, 1636\u20131661 (2014).","journal-title":"Circulation"},{"key":"71437_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jth.12106","volume":"11","author":"JP Galanaud","year":"2013","unstructured":"Galanaud, J. P. et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J. Thromb. Haemost. 11, 474\u2013480 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1538-7836.2005.01216.x","volume":"3","author":"SR Kahn","year":"2005","unstructured":"Kahn, S. R. et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J. Thromb. Haemost. 3, 718\u2013723 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/asheducation-2016.1.413","volume":"2016","author":"SR Kahn","year":"2016","unstructured":"Kahn, S. R. The post-thrombotic syndrome. Hematology 2016, 413\u2013418 (2016).","journal-title":"Hematology"},{"key":"71437_CR9","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","volume":"31","author":"A Undas","year":"2011","unstructured":"Undas, A. & Ari\u00ebns, R. A. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 31, e88-99. https:\/\/doi.org\/10.1161\/ATVBAHA.111.230631 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"71437_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood-2017-07-798306","volume":"131","author":"J Cieslik","year":"2018","unstructured":"Cieslik, J., Mrozinska, S., Broniatowska, E. & Undas, A. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 131, 797\u2013807 (2018).","journal-title":"Blood"},{"key":"71437_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/jth.13264","volume":"14","author":"J Siudut","year":"2016","unstructured":"Siudut, J., Grela, M., Wypasek, E., Plens, K. & Undas, A. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J. Thromb. Haemost. 14, 784\u2013793 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12016-007-8058-6","volume":"34","author":"M Blank","year":"2008","unstructured":"Blank, M. & Shoenfeld, Y. Histidine-rich glycoprotein modulation of immune\/autoimmune, vascular, and coagulation systems. Clin. Rev. Allergy Immunol. 34, 307\u2013312 (2008).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"71437_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/CCM.0000000000002947","volume":"46","author":"K Kuroda","year":"2018","unstructured":"Kuroda, K. et al. Decrease in histidine-rich glycoprotein as a novel biomarker to predict sepsis among systemic inflammatory response syndrome. Crit Care Med. 46, 570\u2013576 (2018).","journal-title":"Crit Care Med."},{"key":"71437_CR14","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1021\/pr300330z","volume":"11","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS\/MS. J. Proteome Res. 11, 4541\u20134552 (2012).","journal-title":"J. Proteome Res."},{"key":"71437_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4149\/neo_2014_001","volume":"61","author":"X He","year":"2014","unstructured":"He, X. et al. Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS\/MS. Neoplasma 61, 17\u201326 (2014).","journal-title":"Neoplasma"},{"key":"71437_CR16","first-page":"593","volume":"34","author":"LD Johnson","year":"2014","unstructured":"Johnson, L. D., Goubran, H. A. & Kotb, R. R. Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res. 34, 593\u2013603 (2014).","journal-title":"Anticancer Res."},{"key":"71437_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1055\/s-0031-1276588","volume":"37","author":"S Wakabayashi","year":"2011","unstructured":"Wakabayashi, S. & Koide, T. Histidine-rich glycoprotein: a possible modulator of coagulation and fibrinolysis. Semin. Thromb. Hemost. 37, 389\u2013394 (2011).","journal-title":"Semin. Thromb. Hemost."},{"key":"71437_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1440-1711.2005.01320.x","volume":"83","author":"AL Jones","year":"2005","unstructured":"Jones, A. L., Hulett, M. D. & Parish, C. R. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol. Cell. Biol. 83, 106\u2013118 (2005).","journal-title":"Immunol. Cell. Biol."},{"key":"71437_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1538-7836.2005.01238.x","volume":"3","author":"N Tsuchida-Straeten","year":"2005","unstructured":"Tsuchida-Straeten, N. et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J. Thromb. Haemost. 3, 865\u2013872 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR20","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.1038\/s41598-018-35034-x","volume":"8","author":"A Stachowicz","year":"2018","unstructured":"Stachowicz, A. et al. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. Sci. Rep. 8, 17301 (2018).","journal-title":"Sci. Rep."},{"key":"71437_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.1987.tb02357.x","volume":"67","author":"L Engesser","year":"1987","unstructured":"Engesser, L., Kluft, C., Bri\u00ebt, E. & Brommer, E. J. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br. J. Haematol. 67, 355\u2013358 (1987).","journal-title":"Br. J. Haematol."},{"key":"71437_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0049-3848(93)90027-L","volume":"69","author":"G Castaman","year":"1993","unstructured":"Castaman, G., Ruggeri, M., Burei, F. & Rodeghiero, F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thromb. Res. 69, 297\u2013305 (1993).","journal-title":"Thromb. Res."},{"key":"71437_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0038-1649562","volume":"70","author":"T Shigekiyo","year":"1993","unstructured":"Shigekiyo, T. et al. Congenital histidine-rich glycoprotein deficiency. Thromb. Haemost. 70, 263\u2013265 (1993).","journal-title":"Thromb. Haemost."},{"key":"71437_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1055\/s-0037-1614086","volume":"84","author":"T Shigekiyo","year":"2000","unstructured":"Shigekiyo, T. et al. Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular characterization. Thromb. Haemost. 84, 675\u2013679 (2000).","journal-title":"Thromb. Haemost."},{"key":"71437_CR25","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000033221.73082.06","volume":"106","author":"JD Mills","year":"2002","unstructured":"Mills, J. D., Ari\u00ebns, R. A., Mansfield, M. W. & Grant, P. J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106, 1938\u20131942 (2002).","journal-title":"Circulation"},{"key":"71437_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood-2010-02-267740","volume":"116","author":"ME Meltzer","year":"2010","unstructured":"Meltzer, M. E. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116, 113\u2013121 (2010).","journal-title":"Blood"},{"key":"71437_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"71437_CR28","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1172\/JCI112435","volume":"77","author":"LL Leung","year":"1986","unstructured":"Leung, L. L. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J. Clin. Invest. 77, 1305\u20131311 (1986).","journal-title":"J. Clin. Invest."},{"key":"71437_CR29","first-page":"377","volume":"129","author":"P Fr\u0105czek","year":"2019","unstructured":"Fr\u0105czek, P., Krzysztofik, M., Stanisz, A. & Undas, A. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study. Pol. Arch. Intern. Med. 129, 377\u2013385 (2019).","journal-title":"Pol. Arch. Intern. Med."},{"key":"71437_CR30","first-page":"572","volume":"128","author":"S Mrozi\u0144ska","year":"2018","unstructured":"Mrozi\u0144ska, S., Cie\u015blik, J., Broniatowska, E. & Undas, A. Unfavorably altered plasma clot properties in women with a HERDOO2 score equal to or greater than 2 and prediction of recurrent venous thromboembolism. Pol. Arch. Intern. Med. 128, 572\u2013579 (2018).","journal-title":"Pol. Arch. Intern. Med."},{"key":"71437_CR31","doi-asserted-by":"publisher","first-page":"30314","DOI":"10.1074\/jbc.M111.253831","volume":"286","author":"TT Vu","year":"2011","unstructured":"Vu, T. T. et al. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma\u2019-chain. J. Biol. Chem. 286, 30314\u201330323 (2011).","journal-title":"J. Biol. Chem."},{"key":"71437_CR32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/j.1538-7836.2012.04798.x","volume":"10","author":"AC Bouman","year":"2012","unstructured":"Bouman, A. C., Smits, J. J., Ten Cate, H. & Ten Cate-Hoek, A. J. Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. J. Thromb. Haemost. 10, 1532\u20131538 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"71437_CR33","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s001340050715","volume":"24","author":"P P\u00f3voa","year":"1998","unstructured":"P\u00f3voa, P. et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 24, 1052\u20131056 (1998).","journal-title":"Intensive Care Med."},{"key":"71437_CR34","doi-asserted-by":"publisher","first-page":"e107483","DOI":"10.1371\/journal.pone.0107483","volume":"9","author":"S Tugues","year":"2014","unstructured":"Tugues, S. et al. Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. PLoS ONE 9, e107483 (2014).","journal-title":"PLoS ONE"},{"key":"71437_CR35","first-page":"28","volume":"129","author":"M Konieczy\u0144ska","year":"2019","unstructured":"Konieczy\u0144ska, M. et al. Knowledge gaps in patients with venous thromboembolism: usefulness of a new questionnaire. Pol. Arch. Intern. Med 129, 28\u201335 (2019).","journal-title":"Pol. Arch. Intern. Med"},{"key":"71437_CR36","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/ATVBAHA.117.308564","volume":"37","author":"S Kattula","year":"2017","unstructured":"Kattula, S., Byrnes, J. R. & Wolberg, A. S. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 37, e13\u2013e21 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"71437_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/464909","author":"M-G Hong","year":"2020","unstructured":"Hong, M.-G. et al. Profiles of circulating histidine-rich glycoprotein associate with chronological age and risk of all-cause mortality. bioRxiv https:\/\/doi.org\/10.1101\/464909 (2020).","journal-title":"bioRxiv"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71437-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71437-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:05:50Z","timestamp":1670349950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71437-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71437"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71437-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14419"}}